Key result
Perioperative β-blockers lower SVTs and ventricular arrhythmias in cardiac surgery, but in noncardiac surgery may increase mortality and strokes while lowering AMIs and SVTs.
Why the study?
Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery?
Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery?
Long-term β-blocker treatment should be continued perioperatively if tolerated, but starting a new β-blocker requires individualized risk-benefit assessment due to potential adverse outcomes in noncardiac surgery.
Answers are grounded in this paper and cite their sources.
Cautions against new β-blocker starts in noncardiac surgery; leaves open individualized strategies pending higher-level evidence.
CLINICAL QUESTION: Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery? BOTTOM LINE: In cardiac surgery, β-blockers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arrhythmias. In noncardiac surgery, β-blockers are associated with a possible increase in mortality and strokes, a lower incidence of acute myocardial infarctions (AMIs) and SVTs, and an increase in bradycardia and hypotension. If tolerated, long-term β-blocker treatment should be continued perioperatively, whereas the decision to start a β-blocker should be individualized, weighing risks and benefits.
No takes yet. Share an insight, caveat, or question.
Blessberger et al. (2015) conducted a review in Cardiac and noncardiac surgery. β-Blockers was evaluated on Mortality and morbidity. Perioperative β-blockers lower SVTs and ventricular arrhythmias in cardiac surgery, but in noncardiac surgery may increase mortality and strokes while lowering AMIs and SVTs.
Synapse has enriched 10 related papers. Consider them for comparative context: